2000
DOI: 10.1016/s0142-9612(00)00044-2
|View full text |Cite
|
Sign up to set email alerts
|

Evaluation of N-succinyl-chitosan as a systemic long-circulating polymer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
50
1
3

Year Published

2003
2003
2012
2012

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 92 publications
(56 citation statements)
references
References 10 publications
2
50
1
3
Order By: Relevance
“…The relatively high blood retention and liver accumulation of the chi-DOX conjugate (Figure 8) may be a result of the free succinyl residue in the chi-DOX conjugate. This result is consistent with a previous report, in which chitosan had a longer duration in systemic circulation when a succinyl group was introduced (Kato et al, 2000). Compared to the chi-DOX conjugate, the DNA/chi-DOX nanocomplex shows even better delivery of doxorubicin to the liver, blood, and the tumor.…”
Section: Cytotoxic Effects Of the Chi-dox Conjugate And Dna/ Chi-dox supporting
confidence: 93%
“…The relatively high blood retention and liver accumulation of the chi-DOX conjugate (Figure 8) may be a result of the free succinyl residue in the chi-DOX conjugate. This result is consistent with a previous report, in which chitosan had a longer duration in systemic circulation when a succinyl group was introduced (Kato et al, 2000). Compared to the chi-DOX conjugate, the DNA/chi-DOX nanocomplex shows even better delivery of doxorubicin to the liver, blood, and the tumor.…”
Section: Cytotoxic Effects Of the Chi-dox Conjugate And Dna/ Chi-dox supporting
confidence: 93%
“…Por meio deste processo, é possível obter: direcionamento de ação para sistema nervoso central (SNC) 92,93 , seletividade de ação [94][95][96] , prolongamento de ação 97 , melhoramento da biodisponiblidade 98 e, ainda, resolução de problemas de instabilidade e baixa solubilidade em preparações farmacêuticas 99,100 . Atualmente, existem na literatura exemplos importantes de pró-fármacos, que utilizam quitosana e derivados como transportadores poliméricos [101][102][103][104][105][106][107][108][109] . Estes polímeros têm se mostrado adequados, pois permitem diminuir ou resolver inconvenientes que determinados fármacos apresentam.…”
Section: Figura 4 Prováveis Mecanismos De Ação De Quitosana Adaptadunclassified
“…N-Succinyl-chitosan (SCS), a water-soluble chitosan derivative, has already been used in the field of drug carrier and wound dressings, due to its excellent biocompatibility and low toxicity. 9 SCS was initially was reported to be used as wound dressing materials. 10 The wound dressings composed of Suc-Chi and gelatin were also developed.…”
Section: Introductionmentioning
confidence: 99%